AI-generated analysis. Always verify with the original filing.
Jade Biosciences, Inc. announced financial results for the fourth quarter and full year ended December 31, 2025, reporting a net loss of $31.9 million for Q4 and $127.4 million for the year, with cash and equivalents of $336.2 million providing runway into the first half of 2028. The company provided pipeline updates including JADE101 Phase 1 interim data expected Q2 2026 and JADE201 first-in-human trial starting Q2 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
and Exhibit 99.1 to this Report are being furnished to the SEC and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act o
Financial Statements and Exhibits. (d) Exhibits. EXHIBIT INDEX Exhibit Description 99.1 Press release issued on March 6, 2026. 104 Cover page interactive data f